

These written materials are not for publication or distribution (directly or indirectly) in or to the United States, Canada, Australia or Japan. They are not an offer of securities for sale in or into the United States, Canada, Australia or Japan.

The securities to which these materials relate have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act. There will not be a public offering of securities in the United States.

NEWS RELEASE



Evolva announces intention for capital increase to support stevia launch and other growth initiatives

26 August 2015 - In order to further strengthen its financial resources for the continued investment in its product portfolio, **Evolva** intends to raise new equity capital. Targeted gross proceeds are around CHF 60 million and are intended to be principally used to advance Evolva's strategy of becoming an integrated supplier of high value innovative ingredients, by:

- Enhancing its manufacturing capabilities by co-investing alongside partners and contractors (including but not limited to its intended 45% participation in stevia in collaboration with Cargill which, subject to a final agreement being reached, will require Evolva to invest low tens of millions USD through 2017)
- Continuing to improve product profitability through improved yeast strains and production processes
- Expanding sales and sales channels for existing ingredients, with a focus on key accounts
- Generating value adding application data for ingredients to enable benefit-based pricing and open up new markets
- Conducting further regulatory studies for its existing product portfolio, most notably in respect of nootkatone, but also for other products, so as to increase their application range and geographies.

The capital increase is expected to be executed in the next few months, most likely by means of a rights offering, subject to market conditions. Evolva has appointed a banking syndicate to manage the transaction. The new shares shall be issued utilising Evolva's authorised share capital. Further details on the intended use of proceeds and the terms of the rights offering will be announced at the time of the launch of the transaction.

- Ends -

Not for publication or distribution in or to the United States, Canada, Australia or Japan

Press/analyst meeting & call at 10.00 AM CET on 26 August 2015

Neil Goldsmith (CEO) and Jakob Dynnes Hansen (CFO) will provide an update on progress in a meeting for analysts and media at the **Park Hyatt Hotel** in Zürich. The presentation is [available on the website](#).

The meeting is also accessible via dial-in:

+41 (0)58 310 50 00 (Europe)

+44 (0)203 059 58 62 (UK)

+1 (1)631 570 5613 (USA)

A replay will be available as a podcast for 2 weeks after the call. The link to the podcast will be posted on Evolva's website.

About Evolva

Evolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva's products include stevia, resveratrol, vanillin, nootkatone, valencene and saffron. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make. For more information see www.evolva.com. Questions about our fermentation approach? Have a look at [our video](#).

Contact Details

Neil Goldsmith, CEO

neilg@evolva.com

+ 41 61 485 2005

Jakob Dynnes Hansen, CFO

jakobdh@evolva.com

+ 41 61 485 2034

Paul Verbraeken, IR

paulv@evolva.com

+ 41 61 485 2035

This document is not an offer to sell or a solicitation of offers to purchase or subscribe for shares. This document is not a prospectus within the meaning of article 652a of the Swiss Code of Obligations, nor is it a listing prospectus as defined in the listing rules of the SIX Swiss Exchange AG or a prospectus under any other applicable laws. Copies of this document may not be sent to jurisdictions, or distributed in or sent from jurisdictions, in which this is barred or prohibited by law. The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, in any jurisdiction in which such offer or solicitation would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction. A decision to invest in securities of Evolva Holding SA should be based exclusively on the issue and listing prospectus to be published by Evolva Holding SA for such purpose.

This document and the information contained herein is not for publication or distribution into the United States of America and should not be distributed or otherwise transmitted into the United States or to U.S. persons (as defined in the U.S. Securities Act of 1933, as amended (the "**Securities Act**")) or publications with a general circulation in the United States. This document does not constitute an offer or invitation to

Not for publication or distribution in or to the United States, Canada, Australia or Japan

subscribe for or to purchase any securities in the United States of America. The securities referred to herein have not been and will not be registered under the Securities Act, or the laws of any state and may not be offered or sold in the United States of America absent registration or an exemption from registration under Securities Act. There will be no public offering of the securities in the United States of America.

The information contained herein does not constitute an offer of securities to the public in the United Kingdom. No prospectus offering securities to the public will be published in the United Kingdom. This document is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "**Order**") or (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

Any offer of securities to the public that may be deemed to be made pursuant to this communication in any EEA Member State that has implemented Directive 2003/71/EC (together with the 2010 PD Amending Directive 2010/73/EU, including any applicable implementing measures in any Member State, the "Prospectus Directive") is only addressed to qualified investors in that Member State within the meaning of the Prospectus Directive.

This publication may contain specific forward-looking statements, e.g. statements including terms like "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Evolva Holding SA and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. Evolva Holding SA assumes no responsibility to up-date forward-looking statements or to adapt them to future events or developments."